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Summary
Linkage disequilibrium (LD) mapping may be a pow-
erful means for genome screening to identify suscepti-
bility loci for common diseases. A new statistical ap-
proach for detection of LD around a disease gene is
presented here. This method compares the distribution
of haplotypes in affected individuals versus that expected
for individuals descended from a common ancestor who
carried a mutation of the disease gene. Simulations dem-
onstrate that this method, which we term “ancestral hap-
lotype reconstruction” (AHR), should be powerful for
genome screening of phenotypes characterized by a high
degree of etiologic heterogeneity, even with currently
available marker maps. AHR is best suited to application
in isolated populations where affected individuals are
relatively recently descended (!∼25 generations) from a
common disease mutation–bearing founder.
Introduction
Linkage mapping of disease loci is based on identifica-
tion of marker alleles that are identical by descent (IBD)
in patients—that is, are transmitted together with a
nearby disease allele from a common ancestor or foun-
der. In genetically isolated populations, a substantial
proportion of apparently unrelated patients may share
chromosomal regions IBD from a remote founder. In
these populations it may be possible to apply mapping
methods that take advantage of the fact that such pa-
tients are IBD for marker alleles primarily in the vicinity
of the disease locus (Stam and Zeven 1981; Sanda and
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Ford 1986; Houwen et al. 1994). Formal analysis of
IBD in population samples is usually based on the eval-
uation of linkage disequilibrium (LD)—that is, nonran-
dom association between individual marker alleles and
disease alleles. LD methods have been employed in a
large number of studies to fine-map disease loci by using
patients from founder populations (Sheffield et al. 1995).
Although there is growing interest in the employment
of LD approaches for initial genome-screening studies
of common diseases with complex inheritance patterns,
to date only a small number of rare, autosomal recessive
disorders have been mapped by such methods (Houwen
et al. 1994; Friedman et al. 1995; Newport et al. 1996).
Although simple measures of association are still com-
monly used for the fine-mapping stage of the localization
of disease genes (see the review by Devlin and Risch
1995), these two-point methods are useful only over
relatively small genetic distances around a disease locus
and therefore are not suitable for genome-screening
studies. Newer methods that evaluate LD overmore than
one locus within a region have been proposed. These
newer approaches are based on searching for genome
regions—rather than alleles—that are shared IBD among
affected individuals. These approaches use more infor-
mation than two-point methods, and thus they may have
greater power and could be suitable for genome
screening.
Several methods have been proposed that formulate
expectations about haplotype or allele frequencies under
an alternative hypothesis that is based on the assumption
that affected individuals are descended from a common
founder (Kaplan et al. 1995; Terwilliger 1995; Devlin
et al. 1996; Lazzeroni 1998). The methods of Kaplan et
al. (1995), Devlin et al. (1996), and Lazzeroni (1998),
however, are not likely to be useful for genome-screening
studies of complex traits. Both Kaplan et al. and Devlin
et al. concluded that their method would be effective
only for mapping of diseases in which a single haplotype
has a current high frequency in disease chromosomes;
this situation is unlikely to occur for any complex trait.
Lazzeroni states that her method is designed for fine-
mapping—that is, for situations in which genes already
have been mapped to a particular chromosomal region.
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In contrast, Terwilliger (1995) presents a method that is
applicable to the genome-screening stage of a study, as
well as to the fine-mapping stage, and, unlike the meth-
ods of Kaplan et al. and Devlin et al., this method makes
no a priori assumption about which allele(s) is overre-
presented on chromosomes from affected individuals.
The statistic in Terwilliger’s test can be used to evaluate
LD at multiple contiguous marker loci.
Terwilliger’s test does not examine haplotypes per se
but combines the likelihood ratio (LR) statistics from
separate LD analyses of each marker. This method does
not make use of all of the information in a haplotype;
for example, allele-frequency differences, between pa-
tients and controls, at contiguous loci may be nonsig-
nificantly different; however, if the haplotype frequencies
are compared, they may be significantly different be-
tween the comparison groups. Thus, intuitively,methods
that directly evaluate LD by using haplotype data should
be more powerful than methods that examine multiple
loci without evaluation of haplotype sharing; but no
direct assessment of this assertion has yet been con-
ducted. We present here an LD-mapping method tar-
geted to genome-screening studies in founder popula-
tions. This likelihood method makes direct use of
haplotype information and assumes, as does Terwilli-
ger’s method, that, under the alternative hypothesis, af-
fected individuals are related to a common founder. We
term this method “ancestral haplotype reconstruction”
(AHR). In our approach, the length of the haplotypes
that is wholly or partially shared by affected individuals
is used in the calculation of the likelihood.
In this paper we present the results of analyses using
simulated data that show AHR to be a powerful method
that is robust to high levels of etiologic heterogeneity
and that thus is suitable for mapping of complex traits.
Furthermore, we demonstrate the additional power that
is obtained from a method that uses haplotype data to
evaluate LD over a series of contiguous loci, by com-
paring AHR with a method that evaluates LD at each
of the markers independently. Although we recognize
that there are several multilocus LD-mapping methods,
for this comparison we use Terwilliger’s method because
(1) its assumptions regarding relationship to a common
founder are similar to those of AHR, (2) its use is not
restricted to the fine-mapping stage, and (3) it makes no
assumption regarding the ancestral allele at eachmarker.
Methods
Description of AHR
AHR computes expected haplotype probabilities,
given a founder haplotype, and estimates the following
four parameters: the most likely position of the disease
locus (x); the proportion of chromosomes, in the sample
of affected individuals, that is likely to have descended
from a common founder (a); the separation time (in
generations) from a common ancestor (g); and the
marker-allele frequencies. These probabilities are con-
ditional on disease status and predict the presence or
absence of LD between markers on chromosomes with
the disease mutation. The observed counts of different
haplotypes in the sample are assumed to be distributed
as a multinomial, and the haplotype probabilities are
used to calculate the likelihood that this putative founder
chromosome will give rise to the observed sample of
disease haplotypes. These calculations are repeated for
each of theH putative founder chromosome types. These
H founder likelihoods are weighted by the probability
that a haplotype will be observed in the population and
are summed to create an overall likelihood for the chro-
mosomal segment (Explicit formulation of the haplotype
probabilities and likelihoods are described in the Ap-
pendix). The likelihood is maximized over x, g, and a
and are compared with the null likelihood. Under the
null hypothesis, marker-allele frequencies are estimated,
and . The parameters x, g, and a, then, are esti-a  0
mated iteratively by the maximum-likelihood method,
and marker-allele frequencies are estimated by counting
of chromosomes and the best estimate of a (see below).
Since the parameters x and g are meaningless under the
null hypothesis when , the distribution of the LRa  0
is uncertain in this setting. This type of situation is a
boundary problem that can arise in some LR statistics;
the admixture test for homogeneity (Ott 1983) and Ter-
williger’s (1995) LR test, for example, both estimate pa-
rameters under the alternative that are unidentifiable un-
der the null hypothesis. Faraway (1993) suggests that
the null distribution of the LR in these cases has half its
weight concentrated on 0 and the other half on a dis-
tribution that can be approximated asmax(X1,X2)where
X1 and X2 are independent variables. We used the2x1
formula provided by Faraway (1993) to calculate the
quantiles of this distribution so that one may calculate
threshold LOD scores for different P values. This for-
mula is a simple function of the distribution.2x
AHR requires estimates of marker-allele frequencies
in the population, in order to calculate these haplotype
probabilities. As described above, marker-allele frequen-
cies are treated as nuisance parameters and are estimated
separately under the null and the alternative hypotheses,
by counting of chromosomes in the observed data. Es-
timation of allele frequencies is tied to the estimation of
the parameter a: as a approaches 1.0, frequencies are
estimated primarily on the basis of normal chromo-
somes; as a approaches 0, information from chromo-
somes of patients is incorporated into the estimation of
allele frequencies. Under the null hypothesis (where
), marker-allele frequencies are estimated on thea  0
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basis of both the normal and patient samples (see the
Appendix).
Simulations
We tested the power of AHR on simulated data. Each
simulated chromosome had three markers, each with
four alleles. The disease gene was located halfway be-
tween the first two markers. Assuming that the disease
mutation, on introduction into the population, was in
complete LD with a particular haplotype, and given the
marker-allele frequencies in the population and the num-
ber of generations since the disease mutation was intro-
duced into the population, one can calculate the ex-
pected haplotype distribution in the current population
of chromosomes carrying the disease mutation (see the
Appendix). In simulations, true affected chromosomes
were randomly selected from this expected haplotype
distribution, and normal chromosomes were sampled
from a haplotype distribution under the assumption of
linkage equilibrium (LE). The population from which
simulation samples were collected was assumed to be
exactly 15 generations removed from a common ances-
tor (in contrast, in actual data sets, this would be an
average). This value of g was used because it is approx-
imates what we expect in many of the actual populations
in which we envision that AHR will be useful (e.g., those
of Quebec, Costa Rica, or the Ashkenazi Jews). We rea-
soned that, over this number of generations, much of
the IBD with the original founder chromosome would
likely have decayed through recombination.With regard
to the region around a disease gene, however, some af-
fected individuals should remain IBD over chromosomal
segments that are large enough to be detected by genome
screening with currently available markers—for exam-
ple, segments of ∼5 cM.
As with any inherited trait, the effect of a susceptibility
allele for a complex trait can range from dominant to
recessive. We presume that LD analysis for recessive
traits will be more powerful than it is for dominant traits
(Chapman and Wijsman 1998), for the following rea-
sons. At a particular locus that is contributing to disease
susceptibility (for both simple and complex traits), under
recessive transmission, both parents must be transmit-
ting alleles on “disease chromosomes.” In simple dom-
inant traits, the disease chromosome is identified as the
chromosome inherited from the affected parent. Under
dominant transmission, however, the presence of incom-
plete penetrance in complex traits makes it difficult to
identify the disease chromosome; it may not be possible
to differentiate, a priori, between the chromosome con-
taining a susceptibility allele and the normal chromo-
some. Therefore, for dominant transmission of a com-
plex trait, one would expect50% of the chromosomes
to be actually nondisease chromosomes and to add noise
to the IBD signal. This is true even when chromosomal
phase can be unambiguously determined. To assess the
power of AHR in a situation in which we could not
differentiate between a disease and normal chromosome,
simulations were performed under the assumption that
individuals needed only one copy of the disease allele in
order to become affected. In the simulation models, the
penetrance, in affected individuals, of genotypes DD
(i.e., two disease alleles at the disease locus) and DN
was .80, and the probability of disease in individuals
with genotype NN was varied to produce different levels
of etiologic heterogeneity. Under etiologic heterogeneity
we include phenocopies, locus heterogeneity, and allelic
heterogeneity, since these will all have an identical im-
pact on the probability of detection of a disease locus,
when AHR is used. In simulations, the disease-gene fre-
quency was .01. These transmission models were used
only to simulate data; AHR does not require specifica-
tion of the model.
In our simulations, we varied the amount of etiologic
heterogeneity in the affected sample, for a given trans-
mission model and disease-gene frequency, by changing
the probability of disease in NN individuals. If the frac-
tion of affected individuals with genotype DD is x and
the fraction of affected individuals with genotype DN is
y, then, in the sample of chromosomes forming the pa-
tient sample, will be the proportion ofA  n[x .5(y)]
chromosomes that are true disease chromosomes—that
is, IBD from a common founder. In these simulations,
we examined heterogeneity corresponding to A 
, 30%, 20%, and 10%. For each level of hetero-50%
geneity, we simulated by using marker-map spacings of
1, 2, 4, 6, 8, and 10 cM. Each marker had four equally
frequent alleles, in all simulations. Additional simula-
tions were performed (at and a marker densityA  20%
of 4 cM) to assess the effect of (1) different numbers of
alleles at each marker (we examined markers with two
and six equally frequent alleles per marker) and (2) the
frequency of the associated alleles at each marker (we
used markers with four alleles, and the frequency of the
associated allele was 10% or 50%, with equal frequen-
cies for the remaining alleles.
We tested AHR in comparison with Terwilliger’s mul-
tipoint LD LR test (MLD). To put these simulation con-
ditions in terms of l (the parameter estimated byMLD),
these combinations of map spacing and heterogeneity
resulted in the true l for markers closest to the disease
locus to range from .46 ( ; 1-cM map) to .06A  .50
( ; 10-cM map). For each set of simulation con-A  .10
ditions, we generated 100 replicate populations, and, for
each of these 100 populations, a sample of patient chro-
mosomes and a sample of normal chromosomes were
generated. Sample sizes of 200 and 400 chromosomes
were investigated, and both AHR and MLD were ap-
plied to the same data. After the 100 populations were
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Figure 1 Percent of 100 simulation replicates that obtained re-
sults significant, at the and levels, for MLD andP  .01 P  .0001
AHR. Simulations were performed under the assumption that there
are four equally frequent alleles at each marker and that the common
ancestor of the affected individuals lived 15 generations ago. Sample
sizes of 200 or 400 affected and normal chromosomes were used. Four
different conditions of etiologic heterogeneity were examined. “A”
denotes the percent of chromosomes in the affected sample that are
true disease chromosomes descended from a common ancestor.
generated, the power of both methods was evaluated in
terms of the percent of replicates that resulted in LR
statistics corresponding to one-sided P values .0001
(the traditional threshold for statistical significance in
mapping studies) and to P values.01 (used as a thresh-
old for detection of segments of possible interest in initial
genome screening), the same thresholds used by Ter-
williger (1995). When the formula provided by Faraway
(1993) is used, these values correspond to LOD thresh-
olds of 3.29 and 1.44, respectively. The false-positive
rate for both methods was determined on the basis of
two sets of simulations. In one set, 10,000 replicates
were simulated under the null hypothesis of LE, for a
sample size of 400 chromosomes, 3 markers, and two
equally frequent alleles at each marker; in the second
set, 1,000 replicates were simulated under the null hy-
pothesis, for a sample size of 200 chromosomes, 10
markers, and four equally frequent alleles at each
marker. The second set of simulations was designed to
assess the robustness of the false-positive rate estimate
both to changes in the number of markers tested and to
the number of alleles per marker.
Results
The power of both AHR and MLD to detect a disease
locus under different degrees of heterogeneity and with
marker maps of varying density is presented in figure 1,
for simulations using four equally frequent alleles at all
markers. Both AHR and MLD perform well with low
degrees of etiologic heterogeneity and with very densely
spaced markers, and they perform poorly under high
degrees of heterogeneity and with widely spaced mark-
ers. Under intermediate scenarios, however, AHR con-
sistently outperforms MLD. This advantage of AHR is
observed at significance thresholds that might be used
in detection of regions of possible interest ( ), asP ! .01
well as at more-stringent thresholds of statistical signif-
icance ( ). In the genome-screening stage of aP ! .0001
mapping project, relatively few individuals are genoty-
ped by use of spaced markers, and a low threshold for
significance is employed to detect regions for more-in-
tensive study. With sample sizes of 100 case and control
individuals and a 6-cM map (this marker density is cur-
rently commonly considered for genome screens in pop-
ulations), the power of AHR at significance level .01
was high for several conditions of etiologic heteroge-
neity: 100% for , 95% for , and 69%A  50% A  30%
for . The power of MLD was also high forA  20%
and ; however, the power forA  50% A  30% A 
with a 6-cM map was only 41%. For the highest20%
heterogeneity level considered ( ), both meth-A  10%
ods have very low power with a 6-cM marker map.
Genome screening with a slightly denser map (4 cM)
affords a considerable increase in the power of AHR,
especially at higher levels of heterogeneity; for example,
at , power at the .01 level was 98% for AHR,A  20%
compared with 64% for MLD.
Genome areas that pass an initial threshold are usually
then further explored, with a denser marker map and,
possibly, with more individuals, in the hope that in-
creased statistical significance will be obtained. With
sample sizes of 100 cases and controls, marker-map den-
sities 4 cM, and heterogeneity levels of , theA  20%
power at the .0001 level was 70% for AHR. The
power of MLD was substantially less when ,A  20%
for all marker maps considered. Increasing the sample
size from 100 to 200 individuals (i.e., from 200 to 400
chromosomes) enables both methods to maintain higher
power levels for wider marker-map spacing when there
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Table 1
Average Estimates of a ( ) and Percent of Replicates with an  600
Result Significant at That Identified Correct DiseaseP  .0001
Position and Correct Disease-Bearing Haplotype, for Four Levels of
Etiologic Heterogeneity
A
AVERAGE
ESTIMATED
a, BY
AHR
% (NO.) OF REPLICATES, WITH SIGNIFICANT
RESULTS, THAT CORRECTLY IDENTIFY
Disease Position
Disease Position
and Founding HaplotypeaAHR MLD
.50 .54 .97 (572) .42 (568) .95 (572)
.30 .29 .87 (393) .48 (327) .86 (393)
.20 .20 .72 (300) .36 (137) .72 (300)
.10 .13 .68 (126) .75 (4) .68 (126)
NOTE.—Simulations used four equally frequent alleles at each
marker and sample sizes of 100 cases and 100 control individuals.
a Data are for AHR only (they are not applicable for MLD).
Figure 2 Effect of different numbers of alleles at each marker (left) and frequency of associated marker alleles (right) on the power of
MLD and AHR. Simulations were performed under the assumptions that the marker map has an average density of 4 cM, that there are 200
case and control chromosomes, that there have been 15 generations since a common founder, and that the alleles are equally frequent (left)
and that there are four alleles at each marker for (right). The results for four alleles (left) and frequency .25 (right) are from the same simulation.
For each method, power is measured as the percent of 100 simulations replicates that obtain results significant at the level.P  .0001
are 80% normal chromosomes in the patient sample;
however, at the highest heterogeneity level considered
(90% normal chromosomes in the patient sample), the
power of MLD is low even with a sample of 200 affected
individuals. At this heterogeneity level and sample size,
power at the .0001 level was 94% for a 2-cM map and
33% for a 4-cM map, when AHR was used, compared
with 2% and 1%, respectively, when MLD was used.
Additional simulations (4-cM average map density,
, 200 case and control chromosomes) dem-A  20%
onstrate that, when either all markers have only two
alleles or the frequency of the associated allele is high
at all markers, the powers of MLD and AHR are very
similar and quite low (fig. 2). Increased power is
achieved with either an increase in the number of alleles
per marker or a decrease in the frequency of the asso-
ciated allele; and, in these situations, the power of AHR
is greater than that of MLD.
In all simulations presented in figures 1 and 2, the true
position of the disease locus was midway between two
markers. When the true position was, instead, one-quar-
ter of the distance from one marker to the next (making
the disease locus three times closer to one marker than
to the other), the power results for a single set of sim-
ulations (4-cM average marker density, , 200A  20%
case and control chromosomes, four equally frequent
marker alleles) were virtually unchanged, for both
methods.
In addition to having high power under different con-
ditions, AHR produced relatively accurate estimates of
both the heterogeneity parameter a and the disease lo-
cation. The average estimate of a was similar to the true
simulated level of heterogeneity, and, when a significant
result was found, in the majority of cases the correct
disease interval and founder haplotype were identified
(table 1), whereas MLD identified the correct disease
interval less often than did AHR. These results are ex-
panded in figure 3, where power results for A  50%
and are displayed for and whereA  20% P ! .0001
the correct disease interval was identified. Under con-
ditions of low heterogeneity ( ), both methodsA  50%
are powerful for all marker maps; however, MLD is
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Figure 3 Comparison of the power of MLD and AHR, for two definitions of power: only (circles) and and correctP ! .0001 P ! .0001
disease interval identified (squares), for two different heterogeneity conditions. Simulations were performed under the assumptions that there
are four equally frequent alleles at each marker and that the common ancestor of the affected individuals lived 15 generations ago. Sample
sizes of 200 case and control chromosomes were used. The results indicated by circles are also presented in figure 1 and are replotted here to
facilitate the comparison.
much less accurate. As discussed above, although denser
marker maps afford an increase in power in heteroge-
neous conditions ( ), the signal is not as clearlyA  20%
localized. When less-dense marker maps are used, the
LD signal is more clearly associated with the correct
marker interval; however, overall power is lower (as is
also shown in fig. 1).
Although an accurate, powerful test is desirable, it is
also important to have a low type I–error rate. We eval-
uated the false-positive rates for AHR and MLD in
10,000 simulations, in the absence of a disease locus
(100% normal chromosomes in the patient sample), us-
ing 200 affected individuals, two alleles at each marker,
and equal allele frequencies. The fraction of false-posi-
tive results for nominal P values of .01, .001, and .0001
were .015, .0014, and .0002, respectively, forMLD, and
.0075, .0005, and 0, respectively, for AHR. False-posi-
tive results from the set of 1,000 simulations using 10
markers (each with four equally frequent alleles) were
evaluated only for AHR. The fraction of false-positive
results for nominal P values of .01 and .001 were .008
and .001, respectively. Thus, the results for AHR con-
form reasonably well to the false-positive rate predicted
by asymptotic theory.
Discussion
Increased attention is focusing on the possibility that
genomewide association studies, using population sam-
ples, could be the approach of choice for the mapping
of loci for complex traits (Risch and Merikangas 1996).
It is likely that such population genetic–mapping studies
will be implemented initially in relatively recently
founded isolated populations (Freimer et al. 1997).Most
previous LD-mapping studies in isolated populations in-
volved small samples of individuals affected with simple
recessive diseases (e.g., Houwen et al. 1994), in which,
in some cases, statistical analyses may not even be nec-
essary for isolation of the disease gene (Bull et al. 1998).
Common diseases with a complex mode of inheritance
have been a challenge to all mapping methods. Linkage
studies have not worked well to identify susceptibility
genes for such diseases, and current LD methods, even
when employed in isolated founder populations, are
likely to suffer loss of power from the high degree of
etiologic heterogeneity expected for complex traits. Our
simulations indicate that, under conditions of increased
etiologic heterogeneity, AHR is more powerful than
methods that look at loci independently.
AHR does not use a perfect model, and it makes sim-
plifying assumptions regarding the pedigree and evolu-
tionary history that connects the affected individuals, as
do many approaches based on reconstruction of ances-
tral chromosomes. Rannala and Slatkin (1998) dem-
onstrate that methods similar to AHRwill producemax-
imum-likelihood estimates when the gene genealogy of
the affected individuals is a “star” genealogy. A gene
genealogy describes how present-day alleles are related
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both to one another and to a common ancestor. In a
star genealogy, the endpoints of the gene-genealogy tree
are all equidistant from the root, implying that, at the
locus in question, individuals are related only through
one common ancestor and are essentially independent
from one another. Such a genealogy may arise in rapidly
growing populations (Slatkin and Hudson 1991). When
the assumption of a star genealogy is approximately cor-
rect, as in our simulations, we have demonstrated AHR
to be general enough to adequately represent the process
that has produced the sample of affected individuals.
Additionally, the use of linkage equilibrium for the null
likelihood could be problematic for fine marker spacing
(e.g., !1 cM) and/or a very young population (!6 gen-
erations), because of the potential for “background” LD
(BLD) between markers—that is, LD unrelated to a dis-
ease phenotype (Peterson et al. 1995; Laan and Pa¨a¨bo
1997). Since AHR is targeted to the genome-screening
stage, where markers will be relatively far apart (the
appropriate marker map spacing for a genome screen
varies with the age of the population (e.g., see te Meer-
man et al. 1995), the impact of BLD may be minimal.
When strong BLD exists in the absence of a disease locus,
it may produce isolated false-positive results. When a
true disease locus is nearby, BLD may add noise to the
disease-associated LD signal and may weaken the power
of the test. It is clear that, in order for LD mapping of
disease genes to be applied widely (regardless of the
method used), it will be necessary to obtain both a fuller
assessment of the extent and strength of BLD in various
populations and a greater understanding of the factors
that influence BLD. We have previously suggested that
the pattern of LD surrounding disease genes in isolated
populations may be distinct from the pattern of BLD
(Freimer et al. 1997). Empirical studies comparing AHR
with methods used for analysis of BLD both in regions
surrounding disease genes and in anonymous genome
regions (in individuals who carry disease alleles and in
controls) will help to clarify these issues.
Appropriate thresholds for the establishment of sig-
nificant linkage have been proposed (Lander and Krug-
lyak 1995) and have been formulated to account for the
multiple-testing situation that is a consequence of ge-
nome screening. In this formulation, as the relatedness
among affected individuals decreases, the number of in-
dependent tests (and, consequently, the significance
threshold) increases; for example, Lander and Kruglyak
(1995) indicate a LOD threshold of 3.6 for sibs and 3.8
for second cousins. Consider, for instance, a single pair
of affected siblings. Although the number of genetic var-
iations that could be genotyped in these two patients
might be in the millions (if the technology permits), there
are only a limited number of recombinations that have
occurred in the four meioses that separate these subjects
from their parents. A limited number of tests would
therefore detect all chromosomal segments that these
individuals share or fail to share; additional genotyping
would not provide any more information. Similarly, for
a set of affected sib pairs or affected distant relatives,
there are only a limited number of variants that would
need to be genotyped in order to delineate all chromo-
somal segments shared by the patients, and the exact
number required would depend on both the number of
patients and their degree of relationship. Accordingly,
the number of independent statistical tests that can be
performed on these patients’ genotypes will be limited.
Clearly, the upper limit on the number of independent
statistical tests is equal to the number of variants that
could potentially be tested in the genome, presumably
13 million. To correct for the probability of false-positive
results in that many independent tests, one would need
to aim for a testwise significance level of .81.71# 10
This situation, in which all genetic variants in the ge-
nome would yield virtually independent tests, results in
a sample of patients that might correspond to the testing
of completely unrelated individuals. Whenever related
individuals are tested, a less rigorous correction for mul-
tiple testing would be required, with a lower bound given
by the correction required for very close relatives, such
as siblings, in which a testwise significance level of
corresponds approximately to a genomewide52.2# 10
false-positive rate of .05. We will make no attempt here
to accurately define the testwise significance level re-
quired for each data set, but, on the basis of what has
been shown above, it will be clear that this significance
level will always be between and52.2# 10 1.71#
. For LD analysis, Durham and Feingold (1997)810
have recently used the Poisson clumping heuristic to
overcome multiple-testing problems in searches for ge-
nome segments shared IBD in “unrelated” individuals.
For a given study, a highly conservative guideline would
be to estimate the total number of meioses in the data
set (the number of chromosomes multiplied by the es-
timated number of generations since a common founder)
and, on the basis of this, to calculate the average segment
size shared by chance (in the absence of a disease locus)
by all individuals (Durham and Feingold 1997). On the
basis of this, one could estimate an upper bound to the
number of possible independent tests, and a Bonferroni
correction for this number of tests could be employed;
for example, 50 individuals (100 chromosomes) sepa-
rated by 20 generations have undergone 2,000 meioses,
resulting in an average segment size of 0.1 cM, 33,000
potential tests, and a testwise significance level of
. This is likely to be extremely conservative,61.5# 10
because, over the course of 20 generations, it is very
unlikely that each segment would be independent from
the adjacent segments. In the comparisons presented in
this paper, any correction for multiple testing would be
the same for both AHR and MLD, since both methods
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move a hypothetical disease locus through a fixed map
of markers (for the sake of simplicity, we used the .0001
threshold, to be consistent with the results of Terwilliger
[1995]).
Oftentimes in a genome screen, an initial threshold
less than that considered for genomewide statistical sig-
nificance is used to identify interesting regions for fol-
low-up. In practice, saturating such areas with denser
sets of markers and increasing the size of the sample
tested permits one to distinguish between true and false
positives. This is both why it is important to consider
the power differences that we derive from different sam-
ple sizes and marker maps and why we show power
under thresholds for screening, as well as those for fol-
low-up studies. It is worth noting that examination of
haplotypes will not afford an increase in power in all
situations. When the marker map is not very dense (i.e.,
8 or 10 cM), the power of AHR is very similar to the
power of MLD, which does not use information from
haplotypes (fig. 1). Of course, the marker-map spacing
that is ideal for haplotype detection will vary with the
separation of patients from their common ancestor, and
these actual power results are specific to our simulation
conditions, in which the affected individuals are sepa-
rated by 15 generations from their common disease-
bearing founder. Had simulations been performed with
g larger or smaller, it is likely that the power curves
would be shifted along the X-axis in figure 1 (average
map density [in cM])—to the left (finer map spacing
needed) or the right (higher power with a less dense
map), respectively.
For several isolated founder populations that are cur-
rently being used to map disease genes, it is estimated
that a high proportion of affected individuals are ap-
proximately this distantly removed (i.e., !∼25 genera-
tions) from a small number of common ancestors. A
number of these populations are now sufficiently large
(e.g., those of Costa Rica, Quebec, Iceland, and the Ash-
kenazi Jews) that it is feasible to collect 200 affected
individuals (as in our simulations) or even to obtain
much larger samples. In the employment of AHR, it is
important to keep in mind that the need to construct
haplotypes in cases and controls dictates extra sampling
and genotyping efforts, in that parents or other relatives
must be collected to establish chromosomal phase.
It is often assumed that genomewide association stud-
ies will not be feasible until extremely dense marker
maps are available. This assumption is probably correct
in heterogeneous populations, such as that of the United
States (Risch and Merikangas 1996), or even in more-
homogeneous populations that may be very old, such as
that of Sardinia or Finland; however, the marker density
of current genetic maps is such that it is now realistic
to undertake genome-screening studies in younger foun-
der populations, such as those mentioned in the preced-
ing paragraph, at a marker spacing appropriate for AHR
analyses; for example, assays are now available for au-
tomated genotyping of ∼1,000 microsatellite markers at
a density of4 cM; in our laboratory we are performing
genome screens for complex diseases, using population
samples from Costa Rica and from the Ashkenazi Jews
(Escamilla et al. 1996; Mathews et al. 1997). The con-
ditions in these screening studies approximate those for
which we have shown AHR to be a powerful analysis
method, even in conditions of etiologic heterogeneity. A
great deal of current attention is focused on the devel-
opment of genetic maps based on single-nucleotide pol-
ymorphisms (SNPs) (Wang et al. 1998). Our simulation
results indicating low power, of both AHR and MLD,
for biallelic markers spaced at a density of 4 cM suggest
that very dense SNP maps will be needed even in recently
founded populations, if complex traits are to be mapped
by use of biallelic markers and LD methods. Chapman
and Wijsman (1998) also have stated that extremely
dense marker maps are needed for genome screens with
biallelic markers, and they suggest that, even with mul-
tiallelic markers, single-marker LD testing may be fea-
sible (in terms of power) only for simple Mendelian dis-
eases. Our results demonstrate that multiple-marker LD
tests such as AHR can be powerful for traits with com-
plex transmission, and we anticipate that, under con-
ditions of etiologic heterogeneity, at denser marker spac-
ing, AHR will outperform methods such as MLD, even
when biallelic markers are used.
Our simulations examined a range of heterogeneity
conditions that probably encompass the level of heter-
ogeneity to be expected in many common, complex dis-
eases; for example, in a variety of populations, theAPOE
gene has been implicated in Alzheimer disease
(AD)—with association between the e4 allele of this gene
and increased risk of AD. Samples of patients from dif-
ferent types of AD families report a .20–.50 frequency
of the e4 allele (van Gool et al. 1995). Even at the lower
end of this range, the power of AHR with 100 patients
is good (fig. 1).
In summary, the examination of linkage disequilib-
rium in founder populations is a potentially powerful
way to map and localize disease genes. Complex models
of transmission are not required, and sampling from a
founder population makes use of the many historical
recombinations between markers and disease, enabling
one to pinpoint interesting regions around disease loci.
Extreme heterogeneity in the patient sample has been a
challenge to all LD methods. With sample sizes con-
sisting of as few as 100 individuals, AHR has the po-
tential to perform well under conditions of etiologic het-
erogeneity. In addition to identifying segments
potentially containing disease loci, the method gives in-
formation about the ancestral haplotypes on which the
disease mutation arose.
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Appendix
Consider a chromosome with three markers, A–C, in
which the original disease mutation occurred between
A and B. At the time when the mutation was introduced,
there were na alleles at marker A, nb alleles at marker
B, and nc alleles at marker C. On the chromosome con-
taining the disease-mutation markers A–C carried allele
x. The probability that, after g generations, an affected
individual carrying the original disease mutation would
still have allele x at markers A–C is
g g g g g(1 v ) (1 v ) (1 v )  (1 v ) (1 v )1 2 3 1 2
g g g#[1 (1 v ) ]f(x ) (1 v ) [1 (1 v ) ]3 C 1 2
g g g#f(x )f(x ) [1 (1 v ) ](1 v ) (1 v )B C 1 2 3
g g g#f(x ) [1 (1 v ) ](1 v ) [1 (1 v ) ]A 1 2 3
g g#f(x )f(x ) [1 (1 v ) ][1 (1 v ) ]A C 1 2
#f(x )f(x )f(x ) ,A B C
(A1)
where v1 is the recombination fraction between the dis-
ease and marker A, v2 is the recombination fraction be-
tween the disease and marker B, v3 is the recombination
fraction between markers B and C, g is the number of
generations since founding (i.e., since the mutation was
introduced into the population), and the population fre-
quencies of the x-allele at markers A, B, and C are f(xA),
f(xB) and f(xC), respectively. Equation (A1) includes
terms for the possibility of recombination between the
markers and the disease locus, with the x allele at the
markers then being IBS rather than IBD. The probabil-
ities that an affected individual with the original mu-
tation will have haplotypes other than the founding hap-
lotype x-x-x are calculated similarly. The method as
currently implemented examines three-marker haploty-
pes as described above; however, extension to more
markers is straightforward.
These probabilities assume (1) that there is no inter-
ference in recombination and (2) that the same marker
alleles are present now as were present g generations
ago, in similar frequencies. If, for example, marker A
has na alleles, marker B has nb alleles, and marker C has
nc alleles, where , then these prob-(n ) 7 (n ) 7 (n )  Ha b c
abilities form an transition matrix T, with rowH#H
i containing the probabilities that founder haplotype i
gave rise to each of the H different haplotypes in g gen-
erations. The rows of this transition matrix sum to 1.
In simulations, the haplotype frequencies in the popu-
lation of chromosomes carrying the disease mutation
were formulated on the basis of these transition prob-
abilities, under the assumption that the disease arose on
a haplotype with the “1” allele at each of the three
markers.
Because not all chromosomes in the patient sample
may be true disease chromosomes from a common foun-
der, this basic procedure has been modified to deal with
heterogeneity in the sample of patient chromosomes.
Some fraction, a, of the chromosomes in the patient
sample will be associated with this chromosomal seg-
ment, and ( ) will not be associated with it. We1 a
examine a in steps of .02, from 1.0 to .0, and for each
step in a we produce a new transition matrix. If we call
the transition matrix calculated under the alternative hy-
pothesis (in which the disease locus is hypothesized to
be between markers A and B) “T” and call the transition
matrix calculated under the null hypothesis of linkage
equilibrium “Tn,” then this new transition matrix is cal-
culated as
∗ ( )T  aT 1 a T . (A2)n
Once these transition probabilities are estimated, the
likelihood that a particular founder chromosome will
give rise to the observed sample of patient haplotypes
in g generations is easily estimated; for example, if one
assumes that the disease mutation arose on a chromo-
some with haplotype K, then the likelihood (LK) that
this chromosome was the founder of the present-day
sampled patient chromosomes is given by the
multinomial
H
Y Ni i( )L  (P ) le , (A3)K K,i i
i1
where i indexes the H potential haplotypes for the two
markers, PK,i is the probability that the ancestral disease
chromosome haplotype K gave rise to a haplotype of
type i in g generations (entry K,i of transition matrix T*
from eq. [A2]), lei is the linkage-equilibrium probability
of haplotype i, and Yi and Ni are the observed numbers
of haplotype i in the sample of patient and normal chro-
mosomes, respectively (Si[Yi] is the number of chro-
mosomes from affected individuals in the samples to be
analyzed, and Si[Ni] is the number of normal chromo-
somes in the samples to be analyzed). The likelihood in
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equation (A3) assumes that all individuals are indepen-
dent. Although one might consider that, after many gen-
erations of separation from a common ancestor, these
individuals are independent, they are, in fact, related
through a complex and unknown pedigree. The simpli-
fication of considering that individuals the are indepen-
dent makes the likelihood much more tractable to com-
putation (for an alternative approach using single
biallelic markers, see the work of Rannala and Slatkin
[1998]). In practical application of AHR, it is important
that individuals not be too closely related to each other,
to minimize the possibility of detection of IBD regions
that do not contain disease-susceptibility genes. In pop-
ulation genetic–mapping studies in our laboratory, we
stipulate that affected individuals should not share an-
cestry for at least four generations (although the vast
majority of affected individuals will be more distantly
related to one another). The expected amount of chro-
mosome sharing among such affected individuals, in the
absence of a disease gene (Durham and Feingold 1997),
is below the resolution that we would anticipate for
genome-screening studies using AHR.
The H likelihoods are then summed, and they are
weighted by the probability that a particular haplotype
will be observed in the population, to produce an overall
likelihood:
H
L  f L , (A4) i i
i1
where fi is the frequency of haplotype i in the population.
The haplotype frequencies fi are estimated under the as-
sumption of linkage equilibrium. The a posteriori most
likely “founder” disease chromosome can be identified
as the haplotype that adds the most weight to this sum.
The estimation of marker-allele frequency is tied to
the estimation of the parameter a, and the frequencies
are reestimated with each increment of a. The frequency
of allele x on marker A would be estimated as
( ) ( ) ( )N f x 1 a N f xD A N AD N( )f x  ,A ( )N 1 a ND N
where ND and NN are the number of sampled patient
and normal chromosomes, respectively, and the fre-
quency of allele x on marker A, as estimated on the basis
of patient chromosomes, is f(x)D and, as estimated on
the basis of normal chromosomes, is f(x)N.
The likelihood in equation (A4) is compared with the
null likelihood, which is generated under the assumption
that . This LR is then maximized over a, positiona  0
of the disease locus (x), and g.
Equations (A3) and (A4) parallel the approach taken
by Terwilliger (1995) for two-point analysis of LD be-
tween disease and a single marker locus. When exam-
ining multiple marker loci, Terwilliger sums the log like-
lihoods of equation (A4) for the different markers (at
common values of a and g), whereas AHR examines
entire haplotypes. In equations (A3) and (A4), PK,i, lei,
and fi refer to haplotype frequencies in AHR but are
allele frequencies in Terwilliger’s method.
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